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Abstract
Background: In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with
nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent
with slowing disease progression. However, nintedanib was not associated with a benefit in health-related quality
of life (HRQoL) assessed using the St George’s respiratory questionnaire (SGRQ). We aimed to further examine the
impact of IPF progression on HRQoL and symptoms, and to explore the effect of nintedanib on HRQoL in patients
from the INPULSIS® trials stratified by clinical factors associated with disease progression.
Methods: Patient-reported outcome (PRO) data from the INPULSIS® trials were included in three post hoc analyses.
Two analyses used the pooled data set to examine PRO changes from baseline to week 52 according to 1) decline
in FVC and 2) occurrence of acute exacerbations. In the third analysis, patients were stratified based on clinical
indicators of disease progression (gender, age and physiology [GAP] stage; FVC % predicted; diffusing capacity of
the lung for carbon monoxide [DLCO] % predicted; composite physiologic index [CPI]; and SGRQ total score) at
baseline; median change from baseline was measured at 52 weeks and treatment groups were compared using the
Wilcoxon two-sample test.
Results: Data from 1061 patients (638 nintedanib, 423 placebo) were analyzed. Greater categorical decline from
baseline in FVC % predicted over 52 weeks was associated with significant worsening of HRQoL and symptoms
across all PRO measures. Acute exacerbations were associated with deterioration in HRQoL and worsened
symptoms. In general, patients with advanced disease at baseline (defined as GAP II/III, FVC ≤ 80%, DLCO ≤ 40%,
CPI > 45, or SGRQ > 40) experienced greater deterioration in PROs than patients with less-advanced disease.
Among patients with advanced disease, compared with placebo, nintedanib slowed deterioration in several PROs;
benefit was most apparent on the SGRQ (total and activity scores).
Conclusions: In patients with advanced IPF, compared with placebo, nintedanib slowed deterioration in HRQoL
and symptoms as assessed by several PROs. HRQoL measures have a higher responsiveness to change in advanced
disease and may lack sensitivity to capture change in patients with less-advanced IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive and fibrotic lung disease characterized by declining
pulmonary function leading to respiratory failure and
death [1]. Based on data collected prior to the availability
of antifibrotic therapy, post-diagnosis survival for pa-
tients with IPF is typically 3–5 years [2, 3]. As IPF
worsens, the development of comorbidities, increased
symptom burden and the need for long-term oxygen
therapy contribute to increasing impairments in health-
related quality of life (HRQoL) [4, 5]. Patient-reported
outcomes (PROs) can quantify how a disease may affect
a patient’s HRQoL, and a wide range of PRO measures
have been employed to understand the impact of
HRQoL in IPF [6].
In patients with advanced IPF, as lung function de-
clines, HRQoL follows. Registry studies reveal that a low
forced vital capacity (FVC) % predicted (ie ≤ 50) is asso-
ciated with severe symptoms and poor HRQoL, and a
significant decline in FVC is associated with worsening
symptoms and deterioration in HRQoL [4, 7]. Further-
more, as patients with IPF approach acute exacerbation
or death, they experience an escalating symptom burden
and a rapid decline in HRQoL [5, 8].
In the Phase III INPULSIS® trials, treatment with nin-
tedanib significantly reduced the annual rate of decline
in FVC in patients with IPF, compared with placebo,
reflecting a slowing of disease progression [9]. Addition-
ally, in a prespecified pooled analysis, treatment with
nintedanib significantly increased the time to first adju-
dicated, confirmed or suspected, acute exacerbation of
IPF [9]. However, nintedanib was not associated with a
significant treatment difference in HRQoL as assessed
using the St George’s respiratory questionnaire (SGRQ)
[9], a PRO that has demonstrated acceptable psychomet-
ric properties in IPF [10, 11].
Using data gathered in the INPULSIS® trials, we con-
ducted three post hoc analyses to examine the impact of
the following on HRQoL and symptoms in patients with
IPF: 1) decline in FVC % predicted; 2) occurrence of
acute exacerbations; and 3) treatment with nintedanib.
Methods
INPULSIS® studies
The two INPULSIS® studies were 52-week, randomized,
double-blind, placebo-controlled, parallel-group Phase
III trials, in which patients with IPF received either pla-
cebo or nintedanib 150 mg twice daily [9]. Enrolled pa-
tients had an FVC % predicted ≥ 50% and a diffusing
capacity of the lung for carbon monoxide (DLCO) % pre-
dicted of 30–79%.
The primary outcome measure in the INPULSIS® trials
was the annual rate of decline in FVC [9]. Time to first
acute exacerbation and change from baseline in SGRQ
total score were secondary outcome measures. The
SGRQ comprises three domains (symptoms, activity and
impacts); the total score and the score for each domain
range from 0 to 100, with higher scores indicating worse
HRQoL [10, 12]. The minimal important difference
(MID) for each domain is: 8 (symptoms), 5 (activity) and
7 (impacts and total) [10]. Several other PROs were used
in the INPULSIS® trials: the University of California San
Diego shortness of breath questionnaire (UCSD-SOBQ);
the Cough and Sputum Assessment Questionnaire
(CASA-Q); and the EuroQoL 5-dimensional quality of
life questionnaire (EQ-5D) visual analog scale (VAS).
The UCSD-SOBQ total score ranges from 0 to 120, with
higher scores indicating greater severity of breathless-
ness; the MID is estimated to be 8 (range 5–11) [13].
The CASA-Q comprises four domains (symptom and
impact for cough and sputum); the score for each do-
main ranges from 0 to 100, and lower scores indicate
worse symptoms / greater impact [14]. Data support the
validity of the UCSD-SOBQ and the CASA-Q for asses-
sing target domains in patients with IPF [15]. The EQ-
5D is a generic measure that has been used to assess
HRQoL in IPF [5]. The VAS of the EQ-5D is scored be-
tween 0 and 100, with lower values indicating worse
health [16].
Data analyses
Three post hoc analyses of the pooled dataset from the
INPULSIS® trials were conducted using HRQoL and
symptom data from the PRO measures described above.
For each PRO, median change from baseline at 52 weeks
was evaluated. Patients with a missing FVC value at
week 52 were excluded. Patients with missing values for
a PRO at baseline and/or week 52 were excluded from
the analysis of that PRO. For analysis 1 (see below), sen-
sitivity analyses were conducted that included patients
with imputation of missing values (last observation car-
ried forward [LOCF] or worst observation carried for-
ward [WOCF]).
Analysis 1: impact of decline in FVC on HRQoL and
symptoms
The objective of this analysis was to evaluate change in
HRQoL and symptoms from baseline to week 52 in
three subgroups defined by absolute decline in FVC %
predicted over the study period.
Previously published data show that absolute declines
in FVC % predicted of ≥ 5% or ≥ 10% are associated with
mortality, and the estimated minimal clinically import-
ant difference for FVC % predicted is 2–6% [17, 18]. We
stratified the sample thus: ≤ 5% decline in FVC % pre-
dicted; > 5–≤ 10% decline in FVC % predicted; > 10% de-
cline in FVC % predicted. Data from nintedanib- and
placebo-treated patients were pooled for this analysis.
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Between-groups comparisons were made using two-
group Satterthwaite t-tests.
Analysis 2: impact on HRQoL and symptoms of acute
exacerbations
The objective of this analysis was to compare changes in
HRQoL and symptoms from baseline to week 52 between
patients who experienced investigator-reported acute ex-
acerbations and those who did not. Patients were stratified
into two groups: 1) those who experienced at least one
investigator-reported acute exacerbation, and 2) those
who did not. Between-groups comparisons were made
using two-group Satterthwaite t-tests.
Analysis 3: effect of nintedanib on HRQoL and symptoms
in patients stratified into less-advanced or advanced
disease subgroups
The objective of this analysis was to compare changes in
HRQoL (SGRQ total, symptoms, activity, and impacts;
EQ-5D VAS) and symptoms (UCSD-SOBQ and CASA-
Q) between patients on nintedanib versus placebo,
within subgroups defined as “less advanced” or “ad-
vanced” IPF using baseline measures of disease severity,
including GAP (Gender, Age, Physiology) stage, FVC %
predicted, DLCO % predicted, CPI (composite physio-
logic index), and SGRQ total score (Table 1) [11, 17, 19].
Within-subgroup median treatment differences between
nintedanib and placebo were calculated using the
Hodges–Lehmann estimator, and statistical significance
was determined using the Wilcoxon two-sample test.
Results
Analysis groups
The patient populations of the INPULSIS® trials have
been described previously [9]. Briefly, 1061 patients were
included in the two trials: 638 received nintedanib 150
mg twice daily and 423 received placebo. All patients
from the INPULSIS® trials were planned to be included
in these analyses; numbers of patients included in each
analysis varied according to data availability.
Baseline demographic characteristics were generally
similar across analysis subgroups (Tables 2, 3 and 4).
Patients in different categories of FVC decline over 52
weeks had similar pulmonary function parameters at
baseline (Table 2). Patients who had experienced ≥ 1
acute exacerbation (Table 3) typically had worse pul-
monary function parameters at baseline than those with-
out an acute exacerbation.
Impact of decline in FVC on HRQoL and symptoms
The majority of patients had ≤ 5% decline in FVC % pre-
dicted at week 52; this stratum exhibited only small
changes in HRQoL and symptoms. Compared to pa-
tients in this stratum, the stratum with > 5 to ≤ 10% de-
cline in FVC % predicted had a significantly greater
degree of worsening in symptoms and HRQoL across all
PROs, while patients in the stratum with > 10% decline
in FVC % predicted had even greater worsening in
HRQoL and symptoms (Table 5). In patients with a de-
cline in FVC % predicted of ≤ 5%, there was no differ-
ence between the nintedanib and placebo groups in
changes in HRQoL or symptoms (see Additional file 1:
Table S1).
Sensitivity analyses, in which missing values were im-
puted, showed similar results to the main analyses (sen-
sitivity analyses in patients with ≤ 5% decline in FVC %
predicted at week 52 are presented in Additional file 1:
Tables S2 [LOCF] and S3 [WOCF]).
Impact on HRQoL and symptoms of acute exacerbations
Patients who did not experience an acute exacerbation
during the INPULSIS® studies showed some deterioration
in HRQoL and symptoms. Compared with patients who
had no acute exacerbations, patients with ≥1 acute exacer-
bation experienced numerically greater worsening across
all PROs except the CASA-Q symptom score; these differ-
ences reached statistical significance for the SGRQ (total
and impacts scores) and the UCSD-SOBQ (Table 6).
Effect of nintedanib on HRQoL and symptoms in patients
stratified into less-advanced or advanced disease
subgroups
Stratification resulted in five subgroups with less-
advanced disease (GAP stage I; FVC % predicted > 80%;
Table 1 Classification of subgroups defined by clinical and physiologic indicators of less-advanced disease or advanced disease at
baseline
Clinical measure Subgroup with less-advanced disease Subgroup with advanced disease
GAP stage I II/III
% predicted FVC, % > 80 ≤ 80
% predicted DLCO, % > 40 ≤ 40
CPI ≤ 45 > 45
SGRQ total score ≤ 40 > 40
CPI composite physiologic index, DLCO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, GAP gender, age and physiology, SGRQ St
George’s respiratory questionnaire
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DLCO % predicted > 40%; CPI ≤ 45; SGRQ total ≤ 40) and
five subgroups with advanced disease (GAP stage II or
III; FVC % predicted ≤80%; DLCO % predicted ≤ 40%;
CPI > 45; SGRQ total > 40). At week 52, all stratification
subgroups showed deterioration across almost all PRO
measures. A notable exception to this was CASA-Q
symptom score, for which no subgroups showed any
overall change (Figs. 1 and 2).
Patients with advanced disease typically showed more
deterioration in PROs than those with less-advanced dis-
ease. The exception to this pattern was patients whose
SGRQ total score at baseline was > 40, who showed
much less decline on all SGRQ scores (total, symptom,
activity or impacts) at week 52 than patients whose
SGRQ total score at baseline was ≤ 40 (Fig. 1e and
Fig. 2e).
Among placebo-treated patients with advanced dis-
ease, the greatest changes from baseline were observed
in scores from the UCSD-SOBQ, CASA-Q impact, and
EQ-5D VAS (Fig. 1). Among nintedanib-treated patients
with advanced disease, the greatest changes from
baseline were observed in scores from the SGRQ (total
and impacts) and UCSD-SOBQ (Fig. 2). Nintedanib-
treated patients with advanced disease defined according
to GAP stage or FVC % predicted showed little or no
change from baseline in SGRQ symptom, SGRQ activity,
CASA-Q symptom, CASA-Q impact, and EQ-5D VAS
scores at week 52. Notably, nintedanib-treated patients
whose SGRQ total score was > 40 at baseline showed
no change or small improvements on the SGRQ
(total, symptom, activity or impacts scores) at week
52 (Fig. 2e).
Overall, nintedanib-treated patients showed less decline
in HRQoL measurements than placebo-treated patients
(Fig. 1 versus Fig. 2). Compared with placebo-treated pa-
tients with advanced disease, nintedanib-treated patients
with advanced disease showed significantly less deterior-
ation from baseline to week 52 for several PROs. This was
most apparent on the SGRQ (total and activity scores),
UCSD-SOBQ and EQ-5D VAS (Table 7). The largest
benefit relative to placebo was seen among nintedanib-
treated patients with advanced disease (defined as GAP
Table 2 Baseline characteristics of patients included in the INPULSIS® pooled data set, by category of decline in FVC % predicted
(analysis 1)
≤ 5% decline in FVC (n = 502) > 5 to≤ 10% decline in FVC (n = 201) > 10% decline in FVC (n = 161)
Women, n (%) 104 (20.7) 33 (16.4) 45 (28.0)
Age, years 66.9 (8.2) 65.4 (7.5) 66.4 (7.7)
Time since IPF diagnosis, years 1.7 (1.4) 1.6 (1.3) 1.5 (1.2)
Ethnicity, n (%)
White 287 (57.2) 119 (59.2) 90 (55.9)
Black 2 (0.4) 0 (0) 0 (0)
Asian 149 (29.7) 56 (27.9) 50 (31.1)
Missing 64 (12.7) 26 (12.9) 21 (13.0)
BMI, kg/m2 28.3 (4.4) 28.1 (4.1) 27.0 (4.9)
Smoking history, n (%)
Non-smoker 128 (25.5) 64 (31.8) 50 (31.1)
Ex-smoker 345 (68.7) 132 (65.7) 108 (67.1)
Current smoker 29 (5.8) 5 (2.5) 3 (1.9)
Comorbidities, n (%)
PH 17 (3.4) 6 (3.0) 3 (1.9)
COPD 15 (3.0) 4 (2.0) 2 (1.2)
Lung cancera 3 (0.6) 1 (0.5) 0 (0)
GERD 122 (24.3) 43 (21.4) 42 (26.1)
CAD 48 (9.6) 9 (4.5) 12 (7.5)
FVC, % predicted 79.2 (17.3) 82.0 (18.1) 81.2 (18.0)
FEV1/FVC ratio 81.3 (5.6) 81.2 (5.8) 82.4 (6.7)
DLCO, % predicted 48.1 (13.1) 48.5 (12.4) 46.8 (13.1)
Data are shown in mean (standard deviation), unless otherwise indicated. aLung cancer includes malignant lung neoplasm, squamous cell carcinoma of lung, non-
small-cell lung cancer and metastatic lung adenocarcinoma
BMI body mass index, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1
forced expiratory volume in 1 s, FVC forced vital capacity, GERD gastroesophageal reflux disease, IPF idiopathic pulmonary fibrosis, PH pulmonary hypertension
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stage II/III, DLCO ≤ 40% predicted or CPI > 45) on the
SGRQ activity score. There was a numerical trend towards
a reduction in deterioration from baseline with nintedanib
compared with placebo for some additional PROs, includ-
ing in some subgroups with less-advanced disease. How-
ever, these did not reach statistical significance.
Discussion
In patients with IPF enrolled in the INPULSIS® trials,
greater categorical declines from baseline in FVC % pre-
dicted over 52 weeks were associated with worsening
HRQoL and symptoms across all PRO measures. In the
subgroup of patients with > 10% decline in FVC % pre-
dicted, mean change scores exceeded the MID on all do-
mains of the SGRQ. Experiencing an acute exacerbation
was associated with greater deteriorations in HRQoL and
symptoms over time compared with not experiencing an
acute exacerbation. In the pooled analysis of all subjects,
there was no significant effect of nintedanib on HRQoL.
However, subgroup analyses suggest that in patients with
more advanced disease at baseline, there was significantly
less deterioration in certain HRQoL domains and symp-
tom measures among nintedanib-treated patients com-
pared with placebo-treated patients.
The study finding that greater declines in FVC are as-
sociated with significantly greater worsening of HRQoL
in patients with IPF is in agreement with previously pub-
lished data and supports the validity of the instruments
used. In an Australian IPF registry study of 516 patients,
each 1% decline in FVC % predicted was associated with
a 0.30-point increase (indicating a worsening) in total
SGRQ (P < 0.0001) [7]. In an analysis of the German
INSIGHTS-IPF registry, lower FVC % predicted, higher
GAP stage and higher CPI at baseline were all associated
with higher SGRQ scores [4]. At 1 year of follow-up,
INSIGHTS-IPF patients with stable or improved FVC %
predicted had no significant change in SGRQ total score,
whereas SGRQ total scores worsened by 4 points in pa-
tients with a 0–10% decline in FVC % predicted and by
9 points in patients with a > 10% decline in FVC. Similar
outcomes were seen on the EQ-5D VAS and UCSD-
SOBQ [5]. The Idiopathic Pulmonary Fibrosis–
Table 3 Baseline characteristics of patients included in the INPULSIS® pooled data set, experiencing no acute exacerbations or
experiencing ≥ 1 acute exacerbation (analysis 2)
No acute exacerbations (n = 998) ≥ 1 acute exacerbation (n = 63)
Women, n (%) 209 (20.9) 11 (17.5)
Age, years 66.6 (8.0) 69.3 (7.5)
Time since IPF diagnosis, years 1.6 (1.3) 1.8 (1.4)
Ethnicity, n (%)
White 578 (57.9) 30 (47.6)
Black 2 (0.2) 0 (0)
Asian 304 (30.5) 18 (28.6)
Missing 114 (11.4) 15 (23.8)
BMI, kg/m2 28.0 (4.6) 27.1 (4.1)
Smoking history, n (%)
Non-smoker 281 (28.2) 15 (23.8)
Ex-smoker 670 (67.1) 48 (76.2)
Current smoker 47 (4.7) 0 (0)
Comorbidities, n (%)
PH 30 (3.0) 0 (0)
COPD 25 (2.5) 2 (3.2)
Lung cancera 4 (0.4) 0 (0)
GERD 231 (23.1) 17 (27.0)
CAD 85 (8.5) 3 (4.8)
FVC, % predicted 80.2 (17.8) 69.4 (15.0)
FEV1/FVC ratio 81.5 (5.9) 84.2 (5.5)
DLCO, % predicted 47.5 (13.3) 42.6 (15.2)
Data are shown in mean (standard deviation), unless otherwise indicated. aLung cancer includes malignant lung neoplasm, squamous cell carcinoma of lung, non-
small-cell lung cancer and metastatic lung adenocarcinoma
BMI body mass index, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, DLCO diffusing capacity of the lungs for carbon monoxide, FEV1
forced expiratory volume in 1 s, FVC forced vital capacity, GERD gastroesophageal reflux disease, IPF idiopathic pulmonary fibrosis, PH pulmonary hypertension
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Prospective Outcomes (IPF-PRO) registry is a multicen-
ter outpatient registry of US patients with IPF. IPF-PRO
collects PRO data from patients every 6months. We
eagerly await HRQoL data from this registry; they are
expected to be presented in 2020.
Acute exacerbations have been defined as an acute,
clinically significant respiratory deterioration character-
ized by evidence of new widespread alveolar abnormal-
ity. In this study, a clear numerical decline in HRQoL
and symptoms was observed among patients experien-
cing acute exacerbations compared with those who did
not. Similar findings have been reported by Collard et al.
in a 2013 retrospective review of subjects enrolled in the
Sildenafil Trial of Exercise Performance in IPF (STEP-
IPF) who experienced a respiratory serious adverse event
during the trial. Patients with any acute worsening
showed significantly higher SGRQ and UCSD-SOBQ
scores than those experiencing no acute worsening [20].
Similarly, a 2017 Japanese study showed that acute exac-
erbations resulted in a substantial decrease in activities
of daily living (ADL), and persistent hypoxemia in these
patients was significantly associated with reduced ADL
[21].
Some results from the stratified analyses suggest that
in patients with advanced IPF at baseline, compared with
placebo, treatment with nintedanib is associated with
less deterioration in some HRQoL domains and symp-
toms. Patients with advanced IPF have the most im-
paired HRQoL [4], as well as the poorest survival
outcomes [19], likely due to disease progression. Our re-
sults suggest that, at least among patients with the most
advanced IPF, reducing the rate of FVC decline reduces
impairment in HRQoL and symptoms. This effect was
not apparent in patients with less-advanced disease. A
Table 5 Mean changes from baseline to week 52 in all PROs, reported by patients with ≤ 5%, > 5 to ≤ 10%, or > 10% decline in FVC
% predicted over the study period (analysis 1)
Mean change from baseline to week 52
≤ 5% decline in FVC > 5 to≤ 10% decline in FVC > 10% decline in FVC
SGRQ total score −0.18 (n = 477) 4.84** (n = 194) 13.10***, ‡ (n = 152)
SGRQ symptom score −2.39 (n = 492) 7.46*** (n = 198) 9.40*** (n = 155)
SGRQ activity score 0.78 (n = 486) 5.75** (n = 196) 15.58***, ‡ (n = 154)
SGRQ impacts score 0.28 (n = 482) 4.02* (n = 198) 13.15***, ‡ (n = 153)
UCSD-SOBQ 3.02 (n = 441) 7.65** (n = 176) 15.85***, † (n = 132)
CASA-Q cough symptom scorea 2.47 (n = 495) −3.90** (n = 201) −5.27*** (n = 155)
CASA-Q cough impact scorea 1.38 (n = 495) −6.48*** (n = 200) −8.59*** (n = 156)
EQ-5D VASa −0.69 (n = 490) −4.78** (n = 197) −10.83***, † (n = 151)
CASA-Q cough and sputum assessment questionnaire (symptom and impact score), EQ-5D VAS EuroQoL 5-dimensional quality of life questionnaire visual analog
scale, FVC forced vital capacity, PRO patient-reported outcome, SGRQ St George’s respiratory questionnaire (total, symptoms, activity and impacts score), UCSD-
SOBQ University of California San Diego shortness of breath questionnaire
*P < 0.05; **P < 0.01; and ***P < 0.0001 vs the group with ≤ 5% decline in FVC
†P < 0.01 and ‡P < 0.0001 vs the group with > 5 to ≤ 10% decline in FVC
aDecrease in score indicates worsening health
Table 6 PRO mean changes from baseline to week 52, reported by patients experiencing ≥ 1 acute exacerbation and those
experiencing no acute exacerbations over the study period (analysis 2)
Mean change from baseline to week 52
No acute exacerbations ≥ 1 acute exacerbation
SGRQ total score 3.18 (n = 808) 16.53** (n = 28)
SGRQ symptom score 1.93 (n = 829) 11.09 (n = 29)
SGRQ activity score 4.53 (n = 821) 12.44 (n = 28)
SGRQ impacts score 3.13 (n = 818) 21.27*** (n = 28)
UCSD-SOBQ 6.20 (n = 735) 22.00* (n = 23)
CASA-Q cough symptom scorea −0.63 (n = 835) 0.86 (n = 29)
CASA-Q cough impact scorea −2.37 (n = 835) − 8.94 (n = 29)
EQ-5D VASa − 3.65 (n = 821) −7.31 (n = 29)
CASA-Q cough and sputum assessment questionnaire (symptom and impact score), EQ-5D VAS EuroQoL 5-dimensional quality of life questionnaire visual analog
scale, FVC forced vital capacity, PRO patient-reported outcome, SGRQ St George’s respiratory questionnaire (total, symptoms, activity and impacts score), UCSD-
SOBQ University of California San Diego shortness of breath questionnaire
*P < 0.05;**P < 0.01; and ***P < 0.001 vs ‘no acute exacerbations’ group
aDecrease in score indicates worsening health
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a) b)
c)
e)
d)
Fig. 1 Median absolute change from baseline to week 52 across all assessed PROs in placebo-treated patients, by a) GAP stage, b) % predicted
FVC, c) % predicted DLCO, d) CPI and e) SGRQ total score (analysis 3)
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a) b)
c)
e)
d)
Fig. 2 Median absolute change from baseline to week 52 across all assessed PROs in nintedanib-treated patients, by a) GAP stage, b) % predicted
FVC, c) % predicted DLCO, d) CPI and e) SGRQ total score (analysis 3)
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possible explanation is that the HRQoL measures used
in this study may have a greater sensitivity for change in
advanced disease and not capture more subtle changes
in patients with less-advanced disease. Qualitative inter-
views of patients may add valuable information as to
whether this is the case, and why.
In patients with IPF, adverse effects of pharmacologic
therapy could impair HRQoL. However, among patients
with physiologically stable IPF, the absence of a decline
in HRQoL would suggest that treatment with nintedanib
does not negatively impact HRQoL. Pirfenidone failed to
show a significant benefit compared with placebo in the
improvement of dyspnea (measured by UCSD-SOBQ) in
Phase III trials [22, 23]. Nevertheless, post hoc pooled
analyses of the full Phase III data set revealed signifi-
cantly less deterioration over time in UCSD-SOBQ with
pirfenidone compared with placebo. A significant treat-
ment difference of approximately 4 points on the
UCSD-SOBQ was seen at 12 months in patients with
GAP stage II/III and/or baseline FVC < 80% predicted
[24], almost identical to our findings with nintedanib. A
median treatment difference of 8 points was reported in
patients defined as having more advanced lung function
impairment (FVC < 50% predicted and/or DLCO < 35%
predicted) [25]. An observational study in patients with
daily IPF-related cough suggested that pirfenidone
treatment may improve cough-related quality of life
(QoL) compared to before treatment, although
disease-specific QoL (measured by King's Brief
Interstitial Lung disease [K-BILD]) was unchanged
[26]. The AmbOx trial compared the effects of ambu-
latory oxygen with no oxygen on HRQoL in patients
with interstitial lung disease with isolated exertional
hypoxia. Compared with no oxygen, ambulatory oxy-
gen was associated with significant improvements in
K-BILD questionnaire total score and the breathless-
ness and activity subdomains [27].
A key strength of our study is the inclusion of a large
and well-defined cohort of patients with IPF. The large
numbers support the robustness of our findings. How-
ever, several study limitations should be noted. Although
a broad range of patients were included in the INPUL-
SIS® trials, patients with severe physiologic impairment
(FVC < 50% predicted, DLCO < 30% predicted) were ex-
cluded. The analyses were not prespecified, and thus all
results should be interpreted with caution. Outcomes in
subgroups based on decline in FVC % predicted or oc-
currence of acute exacerbations over 52 weeks were
compared using post-baseline data. Only patients with
available data for each PRO were included in analyses,
and thus bias could have been introduced if missingness
were non-ignorable. However, sensitivity analyses sup-
port the main findings. Investigator-assigned acute exac-
erbations may differ from adjudicated acute
exacerbations. Additionally, there was substantial dispar-
ity in patient numbers in the acute exacerbations ana-
lysis between those who experienced ≥1 acute
exacerbation and those who did not, due to the low
Table 7 Nintedanib-placebo median treatment difference for absolute change from baseline to 52 weeks on each PRO measure, by
stratification subgroup (analysis 3)
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number of patients with acute exacerbations and their
high dropout rate. The timing of acute exacerbation rela-
tive to HRQoL measurement may also have been a factor,
as a recent exacerbation may appear to have a greater im-
pact on HRQoL. It should also be noted that the key
HRQoL measure in this study, the SGRQ, was developed
in patients with asthma or chronic obstructive pulmonary
disease (COPD), not IPF [12]. As such, it may not provide
the most accurate representation of HRQoL in this dis-
ease. Indeed, in most of the advanced disease subgroups,
observed changes in SGRQ scores among placebo-treated
patients did not generally exceed reported MIDs. The
CASA-Q was similarly developed in patients with COPD,
and the lack of change in symptom scores over 52 weeks
suggests this measure may not be not as relevant in pa-
tients with IPF, in whom cough is generally dry [15]. For
future research, the K-BILD questionnaire may be more
appropriate considering its correlation with the EQ-5D
and capacity to record disease-specific aspects of IPF [16].
HRQoL and symptomatic treatment benefits may be
hard to detect in patients with less-advanced disease, be-
cause the relationship between lung function and
HRQoL is not linear and may well depend on other fac-
tors such as loss of physiologic reserve and development
of pulmonary hypertension. Additionally, PRO measures
have a higher sensitivity for change in advanced disease.
Analyses such as these can provide insights into which
PROs detect changes in clinical and physiologic function
in IPF efficiently and accurately, and help to improve
our understanding of the relationship between HRQoL
and symptom burden in IPF.
Conclusions
These analyses provide much-needed new data on the
potential value of HRQoL and symptom scores in clin-
ical trials of patients with IPF. In patients with advanced
IPF, compared with placebo, treatment with nintedanib
was associated with less deterioration in HRQoL. These
findings suggest that, by reducing the annual rate of
FVC decline, nintedanib may have similar beneficial ef-
fects on outcomes that are equally important to patients.
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